Dr. McGregor on Choosing Combo Regimens in Advanced RCC
September 16th 2019Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses how to choose between combination treatments in advanced renal cell carcinoma.
Read More
Dr. McGregor on Unmet Needs in Advanced RCC
July 17th 2019Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses unmet needs in advanced renal cell carcinoma (RCC).
Read More
Dr. McGregor on the Combination of Atezolizumab and Bevacizumab in RCC
June 22nd 2019Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in renal cell carcinoma (RCC).
Read More
Dr. McGregor on Advances Made in the Adjuvant Setting of RCC
June 8th 2019Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses advances made in the adjuvant setting of renal cell carcinoma (RCC).
Read More
Dr. McGregor on the Future of Cabozantinib in RCC
May 24th 2019Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the future of cabozantinib (Cabometyx) in renal cell carcinoma (RCC).
Read More
Dr. McGregor on the Utility of Axitinib/Avelumab in Advanced RCC
May 16th 2019Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the data with the combination of axitinib (Inlyta) and avelumab (Bavencio) in advanced renal cell carcinoma (RCC).
Read More
Dr. McGregor on Frontline Regimens in Advanced RCC
May 10th 2019Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses frontline treatment regimens in advanced renal cell carcinoma (RCC).
Read More
Dr. McGregor on Implications of the FDA Approval of Pembrolizumab/Axitinib in RCC
May 4th 2019Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the clinical implications of the FDA approval of pembrolizumab (Keytruda) and axitinib (Inlyta) in advanced renal cell carcinoma (RCC).
Read More
Dr. McGregor on Whether Patients Need Frontline Combinations in RCC
September 11th 2018Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses whether patients with renal cell carcinoma (RCC) need frontline combination therapy.
Read More